Berger et al. explored the use of P2Y12 inhibitors in non-critically ill hospitalized patients with COVID-19 and found that the addition of P2Y12 inhibitors to therapeutic doses of heparin did not result in increased odds of improvement in organ support-free days within 21 days during hospitalization [3]. The gene discussed is P2RY12; the disease is COVID-19.